Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 1, 1996, Pages 55-66

  Saletu, Bernd ^a,b   Grünberger, Josef ^a   Anderer, Peter ^a   Linzmayer, Leopold ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antiglutamate; CNS sedation; EEG mapping; human psychopharmacology; noopsyche; psychometry; riluzole; thymopsyche

Indexed keywords

PLACEBO; RILUZOLE;

ADULT; ARTICLE; BEHAVIOR; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NEUROPROTECTION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SEDATION; VOLUNTEER;

ADULT; AFFECT; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; CROSS-OVER STUDIES; DELTA RHYTHM; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEUROPROTECTIVE AGENTS; PSYCHOMETRICS; RILUZOLE; THETA RHYTHM; THIAZOLES;

EID: 0029965967     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bensimon, G , Lacomblez, L., Meininger, V., ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994, 330: 585-91.
2. Benoit, E., Escande, D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflügers Arch 1991, 419: 603-9.
3. Martin, D., Thompson, M.A., Nadler, J.V. The neuroprotective agent riluzole inhibits the release of L-glutamate and L-aspartate from slices of hippocampal CA1 area. Brit J Pharmacol 1991, 104: 240.
4. Drejer, J., Honore, T., Meier, E., Schousboe, A. Pharmacologically distinct glutamate receptors on cerebellar granule cells. Life Sci 1986, 38: 2077-85.
5. Cheramy, A., Barbeito, L., Godeheu, G., Glowinski, J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992, 147: 209-12.
6. Cheramy, A., Romo, R., Godeheu, G., Baruch, P., Glowinski, J. In vivo presynaptic control of dopamine release in the cat caudate nucleus: H. Facilitatory or inhibitory influence of L-glutamate. Neurosci 1986, 19: 1081-90.
7. Barbeito, L., Cheramy, A., Godeheu, G., Desce, J.M., Glowinski, J. Glutamate receptors of the quisqualate-kainate subtype are involved in the presynaptic regulation of dopamine release in the cat caudate nucleus in vivo. Eur J Neurosci 1990, 2: 304-11.
8. Mizoule, J., Meldrum, B., Mazadier, M. et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission I. Anti-convulsant properties. Neuropharmacology 1985, 24: 767-73.
9. Rataud, J., Bardone, M.C., Stutzmann, J.M. et al. Riluzole (PK 26124) induces discriminative stimuli in rats. Psychopharmacology 1988, 96: 373.
10. Stutzmann, J.M., Böhm, G.A., Gandolfo, G. et al. Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol 1991, 193: 223-9.
11. Malgouris, C., Bardot, F., Daniel, M. et al. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 1989, 9: 3720-7.
12. Benavides, J., Camelin, J.C., Mitrani, N. et al. 2-Amino 6-trifluoromethoxy benzothiazole, a possible antagonist of the excitatory amino acid neurotransmission: II. Biochemical properties. Neuropharmacology 1985, 24: 1085-92.
13. Tsai, D., Steel, D.J., McPhereson, S., Taylor, C.A., Wood, P.L., Lehman, J. PK 26124 is not a competitive antagonist at NMDA-type receptors. In: Excitatory Amino Acid Transmission. Hicks, T.P., Lodge, D., McLennan, H. (Eds.). Alan R. Liss Inc: New York 1987, 20-3.
14. Anderer, P., Saletu, B., Kinsperger, K., Semlitsch, H. Topographic brain mapping of EEG in neuropsychopharmacology - Part I. Methodological aspects. Meth Find Exp Clin Pharmacol 1987, 9: 371-84.
15. Anderer, P., Semlitsch, H.V., Saletu, B., Barbanoj, M.J. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992, 45: 79-93.
16. Saletu, B., Anderer, P., Kinsperger, K., Grünberger, J. Topographic brain mapping of EEG in neuropsychopharmacology - Part II. Clinical applications (Pharmaco-EEG imaging). Meth Find Exp Clin Pharmacol 1987, 9: 385-408.
17. Bartels, P.H., Subach, J.A. Automated interpretation of complex scenes. In: Digital Processing of Biomedical Imagery. Preston, E., Onoe, M. (Eds.). Academic Press: New York 1976, 101-14.
18. Duffy, F.H., Bartels, P.H., Burchfield, J.L. Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 1981, 51: 455-62.
19. Grünberger, J. Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Maudrich: Wien 1977.
20. Grünberger, J., Linzmayer, L. Computergesteuerte klinischpsychodiagnostische Methoden in der Psychiatrie. Neuropsychiatrie 1991, 4: 89-98.
21. Von Zerssen, D., Koeller, D.M., Rey, E.R. Die Befindlichkeitsskala (B-S) - ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneim-Forsch/Drug Res 1970, 20: 915-8.
22. Fink, M. EEG and human psychopharmacology. Ann Rev Pharmacol 1969, 9: 241-58.
23. Itil, T. Quantitative pharmaco-electroencephalography. In: Psychotropic Drugs and the Human EEG. Itil, T. (Ed.). S. Karger: Basel 1974, 43-75.
24. Herrmann, W.M., Schärer, E. Das Pharmako-EEG und seine Bedeutung für die klinische Pharmakologie. In: Klinische Pharmakologie, 4th Ed. Kuemmerle, H.P., Hitzenberger, G., Spitzy, K.H. (Eds.). Landsberg: München 1986, 1-71.
25. Saletu, B. Psychopharmaka, Gehirntätigkeit und Schlaf. Karger: Basel 1976.
26. Saletu, B. The use of pharmaco-EEG in drug profiling. In: Human Psychopharmacology, Measures and Methods, Vol. 1. Hindmarch, I., Stonier, P.D. (Eds.). John Wiley & Sons: Chichester 1987, 173-200.
27. Saletu, B., Grünberger, J., Linzmayer, L., Stadler, R. Classification and assessment of cerebral bioavaliability of lopirazepam (D-12524) by quantitative EEG and psychometric analysis. Arzneim-Forsch/Drug Res 1980, 30: 513-8.
28. Saletu, B., Grünberger, J., Linzmayer, L. Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers. Brit J Clin Pharmacol 1983, 16: 333-5.
29. Saletu, B., Grünberger, J., Berner, P., Koeppen, D. On differences between 1,5- and 1,4-benzodiazepines: PharmacoEEG and psychometric studies with clobazam and lorazgpam. In: Clobazam: Human Psychopharmacology and Clinical Applications. Hindmarch, I., Stonier, P.D., Trimble, M.R. (Eds.). International Congress and Symposium Series, Nr. 74. Royal Soc Med: London 1985, 23-46.
30. Saletu, B., Grünberger, J., Linzmayer, L. Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry. Int Clin Psychopharmacol 1986, 1: 145-64.
31. Saletu, B., Grünberger, J., Sieghart, W. Pharmaco-EEG, behavioural methods and blood levels in the comparison of temazepam and flunitrazepam. Acta Psychiatr Scand 1986, 332 (74): 67-94.
32. Saletu, B., Anderer, P., Kinsperger, K., Grünberger, J., Sieghart. W. Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping. Int Clin Psychopharmacol 1988, 3: 287-323.
33. Saletu, B , Grünberger, J., Anderer, P., Barbanoj. M.J. Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: Electroencephalographic brain mapping and safety evaluation. Curr Ther Res 1988, 44 (6): 909-37.
34. Saletu, B., Grünberger, J., Linzmayer, L. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: Pharmaco-EEG and psychometric studies. Int J Clin Pharmcol Ther Toxicol 1989, 27 (2): 51-65.
35. Saletu, B., Grünberger, J., Linzmayer, L., Anderer, P. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain - A kava plant derivative. Human Psychopharmacol 1989, 4: 169-90.
36. Saletu, B., Grünberger, J., Linzmayer, L., Semlitsch, H.V., Anderer, P., Chwatal, K. Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone. using EEG mapping and psychometry. Brit J Clin Pharmacol 1994, 37: 145-56.
37. Meador, K.J., Loring, D.W., Abney, O.L. et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993, 34 (1): 153-7.
38. Besser, R., Hornung, K., Theisohn, M., Rothacher, G., Krämer, G. EEG changes in patients during the introduction of carbamazepine. Electroencephalogr Clin Neurophysiol 1992, 83: 19-23.
39. Marciani, M.G., Stefanini, F., Stefani, N., Sabbadini, M., Gigli, G.L., Bernardi, G. Effect of carbamazepine treatment on EEG changes induced by different cortical activation patterns in newly referred epileptic patients. Neuropsychobiology 1992, 25: 221-6.
40. Marciani, M.G., Gigli, G.L., Maschio, M.C., Stefani, N., Stefanini, F., Bernardi, G. EEG changes induced by carbamazepine therapy at rest and during mental processes. Ital J Neural Sci 1992, 13 (9): 729-33.
41. Saletu, B., Grünberger, J., Anderer, P., Linzmayer, L., Konig, P. Acute, central effects of the calcium-channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. ArzneimForsch/Drug Res 1995, 45(I): 217-29.
42. Ehrenberger, K., Felix, D. Glutamate receptors in afferent cochlear neurotransmission in guinea pigs. Heart Res 1991, 52: 73-80.
43. Ehrenberger, K., Felix, D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: In vivo model for drug induced neuroprotection? Neuropharmacology 1992, 31 (12): 1259-63.
44. Denk, D.-M., Felix, D., Ehrenberger, K. Caroverine in the therapy of cochlear synoptic tinnitus: A placebo-controlled blind study. Otolaryngol Head Neck 1993, 109: 128.
45. Saletu, B., Grünberger, J., Anderer, P., Linzmayer, L., König, P. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: Double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia. Brit J Clin Pharmacol 1996, 41.
46. Grünberger, J., Saletu, B., Linzmayer, L., Barbanoj, M.J Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: Psychometric and psychophysiological data. Curr Ther Res 1988, 44 (6): 938-65.
47. Grünberger, J., Saletu, B., Linzmayer, L., Kalk, A., Berner, P. Pharmacodynamic investigations with WE 941, a new triazolodiazepine, by means of psychometric analyses. Curr Ther Res 1978, 24: 427-40.
48. Rodin, E.A., Rim, C.S., Rennick, P.H. The effects of carbamazepine on patients with psychomotor epilepsy: Results of a double-blind study. Epilepsia 1974, 15: 547-61.
49. Gallassi, R., Lorusso, S., Stracciari, A., Morreale, E., Procaccianti, G. Baruzzi, A. Withdrawal of phenobarbital and carbamazepine in epileptic patients: A preliminary neuropsychological report. Acta Neurol Scand 1986, 74: 59-62.